.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,573,293

« Back to Dashboard

Claims for Patent: 6,573,293

Title: Pyrrole substituted 2-indolinone protein kinase inhibitors
Abstract:The present invention relates to pyrrole substituted 2-indolinone compounds and their pharmaceutically acceptable salts which modulate the activity of protein kinases and therefore are expected to be useful in the prevention and treatment of protein kinase related cellular disorders such as cancer.
Inventor(s): Tang; Peng Cho (Moraga, CA), Miller; Todd A. (Bend, OR), Li; Xiaoyuan (Los Altos, CA), Sun; Li (Foster City, CA), Wei; Chung Chen (Foster City, CA), Shirazian; Shahrzad (Corte Madera, CA), Liang; Congxin (Sunnyvale, CA), Vojkovsky; Tomas (San Francisco, CA), Nematalla; Asaad S. (Concord, CA), Hawley; Michael (Kalamazoo, MI)
Assignee: Sugen, Inc. (South San Francisco, CA) Pharmacia & Upjohn Co. (Kalamazoo, MI)
Application Number:09/783,264
Patent Claims: 1. A compound of Formula (I): ##STR208## wherein: R.sup.1 is selected from the group consisting of hydrogen, halo, alkyl, cyclkoalkyl, aryl, heteroaryl, heteroalicyclic, hydroxy, alkoxy, --(CO)R.sup.15, --NR.sup.13 R.sup.14, --(CH.sub.2).sub.r R.sup.16 and --C(O)NR.sup.8 R.sup.9 ; R.sup.2 is selected from the group consisting of hydrogen, halo, alkyl, trihalomethyl, hydroxy, alkoxy, cyano, --NR.sup.13 R.sup.14, --NR.sup.13 C(O)R.sup.14, --C(O)R.sup.15, aryl, heteroaryl, and --S(O).sub.2 NR.sup.13 R.sup.14 ; R.sup.3 is selected from the group consisting of hydrogen, halogen, alkyl, trihalomethyl, hydroxy, alkoxy, --(CO)R.sup.15, --NR.sup.13 R.sup.14, aryl, heteroaryl, --NR.sup.13 S(O).sub.2 R.sup.14, --S(O).sub.2 NR.sup.13 R.sup.14, --NR.sup.13 C(O)R.sup.14, --NR.sup.13 C(O)OR.sup.14 and --SO.sub.2 R.sup.20 (wherein R.sup.20 is alkyl, aryl, aralkyl, heteroaryl and heteroaralkyl); R.sup.4 is selected from the group consisting of hydrogen, halogen, alkyl, hydroxy, alkoxy and --NR.sup.13 R.sup.14 R.sup.5 is selected from the group consisting of hydrogen and alkyl; R.sup.6 is --C(O)R.sup.10 wherein R.sup.10 is --NR.sup.11 (CH.sub.2).sub.n R.sup.12 wherein: R.sup.11 is hydrogen or lower unsubstituted alkyl; n is 2 or 3; and R.sup.12 is --NR.sup.13 R.sup.14 or --N.sup.+ (O)R.sup.13 R.sup.14 ; R.sup.7 is selected from the group consisting of hydrogen, alkyl, aryl and heteroaryl; R.sup.8 and R.sup.9 are independently selected from the group consisting of hydrogen, alkyl and aryl; R.sup.13 and R.sup.14 are independently selected from the group consisting of hydrogen, alkyl, lower alkyl substituted with hydroxy, alkylamino, cyanoalkyl, cycloalkyl, aryl and heteroaryl; or R.sup.13 and R.sup.14 may combine to form a heterocyclo group; R.sup.15 is selected from the group consisting of hydrogen, hydroxy, alkoxy and aryloxy; R.sup.16 is selected from the group consisting of hydroxy, --C(O)R.sup.15, --NR.sup.13 R.sup.14 and --C(O)NR.sup.13 R.sup.14 ; and r is 1, 2, 3, or 4; or a pharmaceutically acceptable salt thereof.

2. The compound or salt of claim 1 wherein: R.sup.6 is --C(O)R.sup.10 wherein R.sup.10 is --NR.sup.11 (CH.sub.2).sub.n R.sup.12 wherein: R.sup.11 is hydrogen or lower unsubstituted alkyl; n is 2 or 3; and R.sup.12 is --NR.sup.13 R.sup.14 wherein R.sup.13 and R.sup.14 are independently unsubstituted lower alkyl; and R.sup.7 is selected from the group consisting of hydrogen, alkyl, aryl and heteroaryl.

3. The compound or salt of claim 1 wherein R.sup.6 is N-(2-dimethylaminoethyl)aminocarbonyl, N-(2-diethylaminoethyl)N-methylaminocarbonyl, N-(3-dimethylaminopropyl)aminocarbonyl, N-(2-diethylaminoethyl)aminocarbonyl, N-(2-ethylaminoethyl)aminocarbonyl, N-(3-ethylaminopropyl)aminocarbonyl, or N-(3-diethylaminopropyl)aminocarbonyl.

4. The compound or salt of claim 1 wherein R.sup.6 is N-(2-diethylaminoethyl)aminocarbonyl or N-(2-ethylaminoethyl)aminocarbonyl.

5. The compound or salt of claim 1, wherein the compound is selected from the group consisting of: ##STR209## ##STR210##

or an L-malate salt thereof.

6. A compound of Formula (I): ##STR211## wherein: R.sup.1 is hydrogen; R.sup.2 is chloro, fluoro, or bromo; R.sup.3 is hydrogen; R.sup.4 is hydrogen; R.sup.5 is methyl; R.sup.6 is --C(O)R.sup.10 wherein R.sup.10 is --NR.sup.11 (CH.sub.2).sub.n R.sup.12 wherein: R.sup.11 is hydrogen or lower unsubstituted alkyl; n is 2 or 3; and R.sup.12 is --NR.sup.13 R.sup.14 wherein R.sup.13 and R.sup.14 are independently unsubstituted lower alkyl; and R.sup.7 is methyl.

7. The compound or salt of claim 1 wherein R.sup.6 is --COR.sup.10 wherein R.sub.10 is --NR.sup.11 (CH.sub.2).sub.n R.sup.12 wherein: R.sup.11 is hydrogen or lower unsubstituted alkyl; n is 2 or 3; and R.sup.12 is --NR.sup.13 R.sup.14 wherein R.sup.13 and R.sub.14 combine to form a group selected from --(CH.sub.2).sub.4 --, --(CH.sub.2).sub.5 --, --(CH.sub.2).sub.2 --O--(CH.sub.2).sub.2 -- and --(CH.sub.2).sub.2 N(CH.sub.3)(CH.sub.2).sub.2 --.

8. The compound or salt of claim 1 wherein R.sub.6 is 3-pyrrolidin-1-ylpropylaminocarbonyl, 3-morpholin-4-ylpropylamino-carbonyl, 2-pyrrolidin-1-ylethylamino-carbonyl, 2-morpholin-4-ylethylaminocarbonyl, 2-(4-methylpiperazin-1-yl)ethyl-aminocarbonyl, 2-(3,5-dimethylpiperazin-1-yl)ethyl-aminocarbonyl, 3-(4-methylpiperazin-1-yl)propylamino-carbonyl or 3-(3,5-dimethylpiperazin-1-yl)propylamino-carbonyl.

9. The compound or salt of claim 1 wherein R.sub.6 is --COR.sub.10 wherein R.sub.10 is --NR.sub.13 R.sub.14 wherein R.sub.13 is hydrogen and R.sub.14 is lower alkyl substituted with hydroxy, aryl, heteroalicyclic, heteroaryl, or carboxy.

10. The compound or salt of claim 1 wherein R.sup.6 is --COR.sup.10 wherein R.sup.10 is --NR.sup.11 (CH.sub.2).sub.n R.sup.12 wherein: R.sup.11 is hydrogen or lower unsubstituted alkyl; n is 2 or 3; and R.sup.12 is --NR.sup.13 R.sup.14 wherein R.sup.13 and R.sup.14 together combine to form a heterocycle.

11. The compound or salt of claim 1 wherein R.sup.6 is --COR.sup.10 wherein R.sup.10 is --NR.sup.11 (CH.sub.2).sub.n R.sup.12 wherein: R.sup.11 is hydrogen or lower unsubstituted alkyl; n is 2 or 3; and R.sup.12 is --NR.sup.13 R.sup.14 wherein R.sup.13 and R.sup.14 together combine to form a 5, 6 or 7 atom heterocycle containing a carbonyl group and one or two nitrogen atoms within the ring.

12. The compound or salt of claim 1 wherein R.sup.6 is 2-(3-oxopiperazin-1-yl)ethylaminocarbonyl, 2-(imidazolidin-1-yl-2-one)ethylaminocarbonyl, 2-(tetrahydropyrimidin-1-yl-2-one)ethylaminocarbonyl, 2-(2-oxopyrrolidin-1-yl)-ethylaminocarbonyl, 3-(3-oxopiperazin-1-yl)propylaminocarbonyl, 3-(imidazolidin-1-yl-2-one)propyl-aminocarbonyl, 3-(tetrahydropyrimidin-1-yl-2-one)-propylaminocarbonyl, or 3-(2-oxopyrrolidin-1-yl)propyl-aminocarbonyl.

13. The compound or salt of claim 1 wherein: R.sup.1 is hydrogen; R.sup.2 is hydrogen, cyano, fluoro, chloro, or bromo; R.sup.3 is phenyl; and R.sup.4 is hydrogen.

14. The compound or salt of claim 1 wherein: R.sup.1 is hydrogen, unsubstituted lower alkyl, --C(O)NR.sup.8 R.sup.9, unsubstituted cycloalkyl or aryl; R.sup.2 is hydrogen, halo, lower alkoxy, cyano, aryl or --S(O).sub.2 NR.sup.13 R.sup.14 wherein R.sup.13 is hydrogen and R.sup.14 is hydrogen, aryl or alkyl; R.sup.3 is selected from the group consisting of hydrogen, lower alkoxy, --C(O)R.sup.15, --NR.sup.13 C(O)R.sup.14, aryl, and heteroaryl; and R.sup.4 is hydrogen.

15. The compound of claim 1 wherein R.sup.6 is --COR.sup.10 wherein R.sup.10 is --NR.sup.11 (CH.sub.2).sub.n R.sup.12 wherein R.sup.12 is --N.sup.+ (O.sup.-)R.sup.13 R.sup.14 wherein R.sup.13 and R.sup.14 are independently selected from the group consisting of unsubstituted lower alkyl.

16. The compound of claim 1 wherein R.sup.6 is 2-[N.sup.+ (O.sup.-)(C.sub.2 H.sub.5).sub.2 ]ethyl-aminocarbonyl.

17. The compound or salt of claim 1 wherein: R.sup.5 is selected from the group consisting of hydrogen, or methyl; and R.sup.7 is selected from the group consisting of methyl, hydrogen or phenyl.

18. The compound or salt of claim 1 wherein: R.sup.1 is hydrogen; R.sup.2 is hydrogen, cyano, chloro, fluoro, or bromo; R.sup.3 hydrogen; and R.sup.4 is hydrogen.

19. The compound or salt of claim 1 wherein: R.sup.1 is hydrogen; R.sup.2 is cyano, chloro, fluoro, or bromo; R.sup.3 is hydrogen; and R.sup.4 is hydrogen.

20. A pharmaceutical composition, comprising a compound or salt of claim 1 and, a pharmaceutically acceptable carrier or excipient.

21. A pharmaceutical composition, comprising a compound or salt of claim 5 and, a pharmaceutically acceptable carrier or excipient.

22. A method for the modulation of the catalytic activity of a protein kinase, comprising contacting said protein kinase with a compound or salt of claim 1 or 5.

23. The method of claim 22 wherein said protein kinase is selected from the group consisting of a receptor tyrosine kinase, a non-receptor tyrosine kinase and a serine-threonine kinase.

24. A method for treating or preventing a protein kinase related disorder in an organism comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound or salt of claim 20 or claim 21 and, a pharmaceutically acceptable carrier or excipient to said organism.

25. The method of claim 24 wherein said protein kinase related disorder is selected from the group consisting of a receptor tyrosine kinase related disorder, a non-receptor tyrosine kinase related disorder and a serine-threonine kinase related disorder.

26. The method of claim 24 wherein said protein kinase related disorder is selected from the group consisting of an EGFR related disorder, a PDGFR related disorder, an IGFR related disorder and a flk related disorder.

27. The method of claim 24 wherein said protein kinase related disorder is a cancer selected from the group consisting of squamous cell carcinoma, astrocytoma, Kaposi's sarcoma, glioblastoma, lung cancer, bladder cancer, head and neck cancer, melanoma, ovarian cancer, prostate cancer, breast cancer, small-cell lung cancer, glioma, colorectal cancer, genitourinary cancer and gastrointestinal cancer.

28. The method of claim 24 wherein said protein kinase related disorder is selected from the group consisting of diabetes, an autoimmune disorder, a hyperproliferation disorder, restenosis, fibrosis, psoriasis, von Heppel-Lindau disease, osteoarthritis, rheumatoid arthritis, angiogenesis, an inflammatory disorder, an immunological disorder and a cardiovascular disorder.

29. The method of claim 24 wherein said organism is a human.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc